We demonstrate that combining a selective cyclin-dependent kinase 2 inhibitor with a DNA damaging agent could be a powerful tool in the clinic for high-grade serous ovarian cancer. This evidence concerns the gene CDK2 and ovarian serous adenocarcinoma.